全文获取类型
收费全文 | 1155篇 |
免费 | 101篇 |
国内免费 | 105篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 46篇 |
妇产科学 | 62篇 |
基础医学 | 238篇 |
口腔科学 | 34篇 |
临床医学 | 164篇 |
内科学 | 234篇 |
皮肤病学 | 8篇 |
神经病学 | 90篇 |
特种医学 | 78篇 |
外科学 | 79篇 |
综合类 | 49篇 |
预防医学 | 69篇 |
眼科学 | 58篇 |
药学 | 83篇 |
中国医学 | 1篇 |
肿瘤学 | 60篇 |
出版年
2021年 | 15篇 |
2020年 | 11篇 |
2019年 | 9篇 |
2018年 | 13篇 |
2017年 | 16篇 |
2016年 | 19篇 |
2015年 | 18篇 |
2014年 | 22篇 |
2013年 | 34篇 |
2012年 | 42篇 |
2011年 | 58篇 |
2010年 | 40篇 |
2009年 | 34篇 |
2008年 | 27篇 |
2007年 | 89篇 |
2006年 | 48篇 |
2005年 | 53篇 |
2004年 | 50篇 |
2003年 | 36篇 |
2002年 | 41篇 |
2001年 | 37篇 |
2000年 | 30篇 |
1999年 | 31篇 |
1998年 | 59篇 |
1997年 | 49篇 |
1996年 | 55篇 |
1995年 | 32篇 |
1994年 | 31篇 |
1993年 | 18篇 |
1992年 | 31篇 |
1991年 | 22篇 |
1990年 | 25篇 |
1989年 | 26篇 |
1988年 | 34篇 |
1987年 | 23篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1978年 | 15篇 |
1977年 | 8篇 |
1976年 | 13篇 |
1975年 | 6篇 |
1974年 | 9篇 |
1973年 | 8篇 |
1970年 | 9篇 |
1968年 | 5篇 |
排序方式: 共有1361条查询结果,搜索用时 15 毫秒
51.
52.
Richard F. Gierczak Laura Pepler Vinai Bhagirath Patricia C. Liaw William P. Sheffield 《Thrombosis research》2014
The M358R variant of alpha-1-proteinase inhibitor (API) is a potent soluble inhibitor of thrombin. Previously we engineered AR-API M358R, a membrane-bound form of this protein and showed that it inhibited exogenous thrombin when expressed on transfected cells lacking tissue factor (TF). To determine the suitability of AR-API M358R for gene transfer to vascular cells to limit thrombogenicity, we tested the ability of AR-API M358R to inhibit endogenous thrombin generated in plasma via co-expression co-expressing it on the surface of cells expressing TF. Transfected AR-API M358R formed inhibitory complexes with thrombin following exposure of recalcified, defibrinated plasma to TF on T24/83 cells, but discontinuously monitored thrombin generation was unaffected. Similarly, AR-API M358R expression did not reduce continuously monitored thrombin generation by T24/83 cell suspensions exposed to recalcified normal plasma in a Thrombogram-Thrombinoscope-type thrombin generation assay (TGA); in contrast, 1 μM hirudin variant 3 or soluble API M358R abolished thrombin generation. Gene transfer of TF to HEK 293 conferred the ability to support TF-dependent thrombin generation on HEK 293 cells. Co-transfection of HEK 293 cells with a 9:1 excess of DNA encoding AR-API M358R to that encoding TF reduced peak thrombin generation approximately 3-fold compared to controls. These in vitro results suggest that surface display of API M358R inhibits thrombin generation when the tethered serpin is expressed in excess of TF, and suggest its potential to limit thrombosis in appropriate vascular beds in animal models. 相似文献
53.
54.
55.
56.
Brains of macaques inoculated with macrophage-tropic, neurovirulent virus 7F, with lymphocyte-tropic SIV mac239, or with dual-tropic SIVmac239/1yE, were examined for microglial activation, astrocyte activation, apoptosis and neuron loss. The brain one animal inoculated with neurovirulent virus 7f showed massive microglial activation as assessed by expression of the major histo-compatibility complex class II (MHC-II). In this animal very numerous, large microglial nodules expressing MHC-II were concentrated in the basal pons and internal capsule. These microglial nodules contained cells undergoing apoptosis detected by in situ end labeling of fragmented DNA. In this animal, neuron loss was apparent near the microglial nodules. In the animals inoculated with SIVmac239 or SIVmac239/17E, pathologic changes such as perivascular cuffing and formation of microglial nodules were absent. However, increased expression of MHC-11 by microglial cells was also concentrated in white matter of the basal pons, midbrain and internal capsule. These results indicate the microglial activation in SIV-infected macaques follows a ventral to dorsal gradient regardless of viral tropism. These results also show that the type and severity of neuropathological changes in SIV-infected macaques is highly dependent on the tropism of the inoculated virus. 相似文献
57.
Auber ML; Horwitz LJ; Blaauw A; Khorana S; Tucker S; Woods T; Warmuth M; Dicke KA; McCredie KB; Spitzer G 《Blood》1988,71(1):166-172
Relatively nonmyelotoxic drugs and drug combinations were investigated for their ability to eliminate malignant cells from human bone marrow. In vitro 90% inhibitory concentration (IC90) doses were established on granulocyte macrophage colony-forming units (GM-CFU) in culture of bone marrow by using the GM-CFU assay for the following drugs: 4- hydroperoxycyclophosphamide (4-HC), Adriamycin, L-asparaginase, bleomycin, hydrocortisone, VP-16, spirogermanium, Taxol, and vincristine. The leukemic cell kill efficiency of these drugs at IC90 doses was compared with that of 4-HC on acute lymphoid leukemia (ALL) cell lines by using the limiting-dilution assay. Under these conditions, no single drug was superior to 4-HC. To increase the in vitro effect in leukemic cell kill, combinations of vincristine with hydrocortisone, Adriamycin, VP-16, and 4-HC were investigated. Vincristine at 1 to 5 micrograms/mL increased the marrow cytotoxicity of hydrocortisone, Adriamycin, and VP-16, but it was protective (subadditive) with 4-HC. Vincristine and 4-HC in combination was additive to supraadditive on ALL cell lines, increased the leukemic cell kill by one to two logs above 4-HC alone at IC90 doses (P less than .05), and was not affected by the addition of excess marrow cells. The recommended doses for chemopurging in clinical studies are vincristine, 1 to 5 micrograms/mL, plus 4-HC, 5 micrograms/mL. 相似文献
58.
Adrian B Levine Jason Peng David Farnell Mitchell Nursey Yiping Wang Julia R Naso Hezhen Ren Hossein Farahani Colin Chen Derek Chiu Aline Talhouk Brandon Sheffield Maziar Riazy Philip P Ip Carlos Parra-Herran Anne Mills Naveena Singh Basile Tessier-Cloutier Taylor Salisbury Jonathan Lee Tim Salcudean Steven JM Jones David G Huntsman C Blake Gilks Stephen Yip Ali Bashashati 《The Journal of pathology》2020,252(2):178-188
Deep learning-based computer vision methods have recently made remarkable breakthroughs in the analysis and classification of cancer pathology images. However, there has been relatively little investigation of the utility of deep neural networks to synthesize medical images. In this study, we evaluated the efficacy of generative adversarial networks to synthesize high-resolution pathology images of 10 histological types of cancer, including five cancer types from The Cancer Genome Atlas and the five major histological subtypes of ovarian carcinoma. The quality of these images was assessed using a comprehensive survey of board-certified pathologists (n = 9) and pathology trainees (n = 6). Our results show that the real and synthetic images are classified by histotype with comparable accuracies and the synthetic images are visually indistinguishable from real images. Furthermore, we trained deep convolutional neural networks to diagnose the different cancer types and determined that the synthetic images perform as well as additional real images when used to supplement a small training set. These findings have important applications in proficiency testing of medical practitioners and quality assurance in clinical laboratories. Furthermore, training of computer-aided diagnostic systems can benefit from synthetic images where labeled datasets are limited (e.g. rare cancers). We have created a publicly available website where clinicians and researchers can attempt questions from the image survey ( http://gan.aimlab.ca/ ). © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
59.
60.
Eliya Farah Maria El Bizri Radmila Day Lavina Matai Fred Horne Timothy P. Hanna David Armstrong Susan Marlin Olivier Jrme Darren R. Brenner Winson Cheung Laszlo Radvanyi Eva Villalba Natalie Leon Chana Cohen Karine Chalifour Ronald Burkes Sharlene Gill Scott Berry Brandon S. Sheffield Pamela Fralick Barry D. Stein 《Current oncology (Toronto, Ont.)》2022,29(3):1723
(1) Background: The COVID-19 pandemic illuminated vulnerabilities in the Canadian health care system and exposed gaps and challenges across the cancer care continuum. Canada is experiencing significant disruptions to cancer-related services, and the impact these disruptions (delays/deferrals/cancellations) have on the health care system and patients are yet to be determined. Given the potential adverse ramifications, how can Canada’s health care systems build resilience for future threats? (2) Methods: To answer this question, CCC facilitated a series of four thought-leadership roundtables, each representing the views of four different stakeholder groups: patients, physicians, health care system leaders, and researchers. (3) Results: Six themes of strength were identified to serve as a springboard for building resilience including, (1) advancing virtual care and digital health technologies to prevent future interruptions in cancer care delivery. (2) developing real-time data metrics, data sharing, and evidence-based decision-making. (3) enhancing public–private-non-profit partnerships to advance research and strengthen connections across the system. (4) advancing patient-centricity in cancer research to drive and encourage precision medicine approaches to care. (5) investing in training and hiring a robust supply of health care human resources. (6) implementing a national strategy and infrastructure to ensure inter-provincial collaborative data sharing (4). Conclusions: A resilient health care system that can respond to shocks and threats is not an emergency system; it is a robust everyday system that can respond to emergencies. 相似文献